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A B S T R A C T
Background: Exercise capacity is helpful in the management of patients with mitral regurgitation (MR).
However, the determinants of exercise capacity reduction in MR have remained unclear. This study was
designed to objectively assess exercise capacity, identify the echocardiographic predictors of exercise
capacity, and investigate its impact on development of symptoms in asymptomatic degenerative MR.
Methods: A total of 49 consecutive asymptomatic patients (age, 58.9  13.1 years; 82% males) with at
least moderate degenerative MR (effective regurgitant oriﬁce area = 0.40  0.14 cm2; regurgitant
volume = 60.9  19.6 mL) underwent the symptom-limited cardiopulmonary exercise testing for assessing
exercise capacity (peak oxygen uptake, peak V˙O2; the minute ventilation/carbon dioxide production,
V˙E=V˙CO2 slope). All patients also underwent exercise stress echocardiography for detecting exercise-induced
pulmonary hypertension (EIPH) deﬁned by systolic pulmonary arterial pressure (SPAP) 60 mmHg.
Results: The mean peak V˙O2 was 22.6  5.1 mL/kg/min (86.7  14.1% of age, gender-predicted); peak V˙O2
widely varied (48–121% of predicted), and was markedly reduced (<80.4% of predicted) in 24% of the study
patients. The patients with EIPH had lower 2-year symptom-free survival than those without EIPH
(p = 0.003). The multivariable analysis demonstrated that EIPH was an independent echocardiographic
determinant of peak V˙O2 (p = 0.001) and V˙E=V˙CO2 slope (p = 0.021). Furthermore, the area under curve of
age- and gender-adjusted exercise SPAP was 0.88 (95% conﬁdence interval: 0.78–0.97) for reduced exercise
capacity.
Conclusions: In asymptomatic moderate to severe degenerative MR, EIPH was independently associated
with exercise capacity and predicted the occurrence of symptoms. Exercise stress echocardiography is an
important tool in managing patients with asymptomatic degenerative MR.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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The limitations in exercise and physical activity play a crucial
role in the management of patients with mitral regurgitation (MR)
[1]. No limitations are clinically observed in asymptomatic* Corresponding author at: Division of Cardiology, Department of Internal
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activity levels into consideration even though most of those
patients are often sedentary. Notable risks are reported in the
subsets of asymptomatic patients with MR [2,3]. The guidelines
appear to underscore the importance of exercise capacity, and
recommend the data assessment of a cardiopulmonary exercise
testing (CPX) [1]. CPX measures variables related to cardiorespira-
tory function, provides noninvasive evaluation of exercise capaci-
ty, and allows risk stratiﬁcation in patients with congestive heart
failure [4]. The current American College of Cardiology/American
Heart Association [5] and European Society of Cardiology [6]
guidelines recommend mitral surgery in asymptomatic patientsgy.
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pulmonary hypertension (PH) deﬁned by systolic pulmonary
arterial pressure (SPAP) >50 mmHg. Likewise, the guidelines
advise operating on such patients in the presence of exercise-
induced PH (EIPH; SPAP 60 mmHg). EIPH may occur even if
resting SPAP is in the normal range [7]. Magne et al. have
demonstrated that EIPH is associated with reduced symptom-free
survival and more accurate than resting PH when predicting the
occurrence of symptoms [8]. However, the potential impact of EIPH
on exercise capacity has not yet been characterized. This study
thus aimed to assess exercise capacity prospectively and objec-
tively and to investigate the inﬂuence of EIPH on exercise capacity
and symptoms in asymptomatic degenerative MR.
Materials and methods
Study subjects
This prospective study included 65 consecutive asymptomatic
patients with degenerative MR, preserved LV systolic function (LV
end-systolic diameter <45 mm and LV ejection fraction >60%) [9]
and at least moderate MR (effective regurgitant oriﬁce area
>0.20 cm2 or regurgitant volume >30 mL) referred for exercise
stress echocardiography between October 2011 and April 2013. The
cardiologists interviewed the study patients and recorded past
medical history. An asymptomatic patient was deﬁned as a patient
who has no speciﬁc symptoms of heart failure, such as shortness of
breath, angina, dizziness, or syncope with exertion. The systematic
interview and physical examination were performed by experienced
cardiologists and symptomatic status was carefully assessed. Of
these, patients with a history of congestive heart failure or SPAP
50 mmHg at rest based on the previous echocardiographic
assessment (n = 3), concomitant valvular stenosis or regurgitation
(n = 3), atrial ﬁbrillation (n = 4), inability to exercise (n = 3), and the
absence of measurable SPAP during exercise (n = 3) were excluded
from this study; ﬁnally, 49 patients were enrolled.
Conventional and exercise echocardiography
Echocardiography was performed in the left lateral decubitus
position using a commercially available system (Vivid E9, General
Electric-Vingmed, Milwaukee, WI, USA). Images were obtained
with a 3.5-MHz transducer in the parasternal and apical views. The
ratio of early (E) to late (A) transmitral velocities (E/A) and
deceleration time of E velocity were obtained using pulsed wave
Doppler in the apical four-chamber view. E0 was measured at the
septal mitral annulus in the apical four-chamber view. The E/E0
ratio was measured to estimate LV ﬁlling pressure [10]. The
severity of MR was measured with the Doppler volumetric method
[11].
All patients underwent a symptom-limited graded bicycle
exercise test in a semi-supine position on a tilting exercise table
(Ergometer & tilt Table 750EC, Lode, Groningen, Netherlands) for
continuous 2D echocardiography. After a 3-min workload at
25 watt (W), the intensity was increased by 25 W every 3 min. The
obtained data were digitally stored. Electrocardiograms, blood
pressure, and heart rate were recorded at each stage. According to
the guidelines [5], EIPH was deﬁned as SPAP 60 mmHg during
exercise.
CPX
All patients underwent CPX on a sitting cycle ergometer
(Accura, Mitsubishi Electrical Engineering Co., Tokyo, Japan) on
different days within 2 weeks before or after exercise echocardi-
ography. After 3-min rest and 4-min warm-up at 20 W, exerciseload intensity was gradually and linearly increased by 1 W or 2 W
per 6 s. The expired gas analysis was performed continuously
throughout the CPX on a breath-by-breath basis with an AE-300
cart (Minato Medical Science, Osaka, Japan). Anaerobic threshold
(AT), peak oxygen uptake (peak V˙O2), and the ventilator equivalent
to carbon dioxide output (V˙E=V˙CO2) slope were obtained from the
results of CPX. Peak V˙O2 was expressed as absolute peak V˙O2 or
normalized peak V˙O2 (percent of age and gender predicted) [12].
Symptom-free survival
Patient follow-up was performed according to the current
guidelines. Patients were classiﬁed as symptomatic when shortness
of breath, angina, dizziness, or syncope with exertion was identiﬁed
during the follow-up. Experienced cardiologists performed the
physical examination and echocardiography and carefully assessed
symptomatic status. Patients were reevaluated every 6 months,
including physical examinations and echocardiography. The inter-
vals of evaluations were shortened to 3 months in patients who
revealed changes compared with the previous measurements or if
echocardiographic measurements were close to the guideline cut-
off values used for surgical indication. At the end of this study,
physicians arranged telephone interviews with patients with the
ﬁnal follow-up at >6 months and reevaluated obtained information.
To ensure blinding and to avoid inﬂuencing the physician’s decision
with exercise echocardiography and cardiopulmonary exercise
testing results, the data on exercise capacity, SPAP, and the
occurrence of EIPH were not sent to the referral physician.
Ethics
This study was performed in accordance with the ethical
principles set forth in the Declaration of Helsinki; the study
protocol was approved by the St. Marianna University School of
Medicine Institutional Committee on Human Research (No. 1288)
in Kanagawa, Japan. Written informed consent was obtained from
all patients prior to their enrollment.
Statistical analysis
Continuous variables are presented as mean  standard devia-
tion and categorical variables are presented as percent. The unpaired
Student’s t test and x2 test were used to compare variables between
the following two groups, the low exercise capacity group and
maintained exercise capacity group determined by ﬁrst quartile of
predicted peak V˙O2 (80.4%). The associations between exercise SPAP
versus peak V˙O2 and V˙E=V˙CO2 slope were investigated using the
Pearson correlation. Multiple linear regression analysis was per-
formed to evaluate the association of peak V˙O2 and V˙E=V˙CO2 slope
with clinical and echocardiographic parameters at rest and peak
exercise. Multivariable linear regression analysis was used to
determine the associations of peak V˙O2 with age, gender, resting
LV end-systolic volume index, E0, regurgitant volume, and EIPH,
respectively. Probabilities of symptom-free survival were obtained by
using the Kaplan–Meier estimates according to the presence of
exercise intolerance or exercise PH and then compared by using the
two-sided log-rank test. Statistical signiﬁcance was set at
p < 0.05. The statistical analysis was performed with commercially
available software (SPSS-18.0 software, SPSS Inc., Chicago, IL, USA).
Results
Patients’ characteristics and echocardiographic parameters
The baseline characteristics are shown in Table 1 according to
the exercise capacity; 12 patients were stratiﬁed into the low
Table 1
Baseline characteristics.
Overall (n = 49) Low exercise
capacity (n = 12, 24%)
Maintained exercise
capacity (n = 37, 76%)
p-Value
Clinical data
Age (years) 58.9  13.1 67.3  11.6 56.2  12.6 <0.0001
Gender male, n (%) 40 (82) 6 (50) 34 (92) 0.001
BMI (kg/m2) 22.6  2.9 22.7  2.7 22.5  3.0 0.845
Rest SBP (mmHg) 137.3  18.4 145.5  21.8 134.0  16.2 0.247
Rest DBP (mmHg) 77.9  10.6 78.6  12.2 77.6  10.1 0.797
Rest HR (beat/min) 76.9  10.6 77.3  12.8 68.7  11.7 0.847
Peak exercise SBP (mmHg) 178.3  25.1 188.2  26.4 171.4  23.4 0.028
Peak exercise DBP (mmHg) 79.9  14.8 81.4  16.8 79.4  14.4 0.691
Peak exercise HR (beat/min) 142.0  14.2 137.3  16.4 144.1  13.4 0.179
Log BNP (pg/mL) 1.5  0.4 1.8  0.5 1.5  0.3 0.017
CPX
AT (mL/min/kg) 15.3  3.2 11.6  2.6 16.4  2.6 <0.0001
Peak V˙O2 (mL/min/kg) 22.6  5.1 16.1  3.0 24.5  3.8 <0.0001
% predicted peak V˙O2 86.7  14.1 66.9  3.0 92.7  8.7 <0.0001
V˙E=V˙CO2 slope 29.1  4.5 33.7  4.7 27.7  3.4 <0.0001
Etiology of MR, n (%)
AML prolapse 9 (18) 2 (17) 7 (19) 0.861
PML prolapse 36 (74) 8 (67) 28 (76) 0.539
Both leaﬂets prolapse 1 (2) 0 (0) 1 (3) 0.565
Sclerotic change 3 (6) 2 (17) 1 (3) 0.080
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; BNP, brain natriuretic peptide; CPX, cardiopulmonary exercise testing;
AT, aerobic threshold; V˙O2, oxygen uptake; V˙E, ventilatory equivalent; V˙CO2, carbon dioxide output; MR, mitral regurgitation; AML, anterior mitral leaﬂet; PML, posterior
mitral leaﬂet.
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exercise capacity group. Of the study patients, 82% were male, 57%
received angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers, 8% received beta-blockers, 22% received calciumTable 2
Resting and exercise echocardiographic data.
Overall (n = 49) Low ex
capacity (n
Resting
LAVI (mL/m2) 53.4  16.0 54.4 
IVST (mm) 8.7  1.2 8.9 
PWT (mm) 8.6  1.1 8.6 
LVDd (mm) 54.7  5.9 53.2 
LVDs (mm) 32.2  4.9 31.3 
LVEDVI (mL/m2) 81.3  16.7 77.0 
LVESVI (mL/m2) 27.8  7.9 25.2 
LVEF (%) 66.7  6.7 67.8 
E/A 1.6  0.6 1.4 
E0 8.2  2.3 7.1 
E/E0 14.0  5.1 15.7 
ERO (cm2) 0.40  0.14 0.35 
RV (mL) 60.9  19.6 53.4 
SPAP (mmHg) 29.7  6.9 30.9 
Exercise
LAVI (mL/m2) 48.3  17.3 46.9 
IVST (mm) 8.8  1.2 8.9 
PWT (mm) 8.7  1.0 8.7 
LVDd (mm) 54.5  6.1 51.8 
LVDs (mm) 30.9  5.6 29.2 
LVEDVI (mL/m2) 85.9  17.3 83.7 
LVESVI (mL/m2) 26.0  7.8 26.9 
LVEF (%) 70.0  7.0 68.5 
E/A 1.4  0.5 1.4 
E0 12.5  4.8 10.7 
E/E0 13.0  6.1 14.0 
SPAP (mmHg) 47.5  12.4 55.8 
EIPH, n (%) 9 (27) 5 (42
LAVI, left atrial volume index; IVST, interventricular septum thickness; PWT, posterior w
end-systolic diameter; LVEDVI, left ventricular end-diastolic volume index; LVESVI, lef
A, the ratio of early diastolic (E) and late diastolic (A) transmitral ﬂow velocities; Dct, de
velocity to early diastolic mitral annular velocity (E0); ERO, effective regurgitant oriﬁce; 
induced pulmonary hypertension.blockers, and 27% received diuretics. The mean peak V˙O2 widely
varied (48–121% of predicted) and was markedly reduced (<80.4%
of predicted) in 24% of the study population. Signiﬁcant differences
in age, gender, and log brain natriuretic peptide (BNP) were foundercise
 = 12, 24%)
Maintained exercise
capacity (n = 37, 76%)
p-Value
 15.5 53.1  16.4 0.807
 1.4 8.6  1.1 0.424
 1.0 8.5  1.1 0.907
 5.1 55.1  6.1 0.320
 5.6 32.5  4.6 0.460
 12.6 82.7  17.8 0.311
 10.6 28.7  6.7 0.190
 10.1 66.4  5.3 0.547
 0.6 1.7  0.6 0.150
 2.1 8.5  2.3 0.064
 6.7 13.4  4.5 0.156
 0.13 0.41  0.14 0.171
 19.1 63.4  19.3 0.127
 7.9 29.3  6.6 0.478
 15.3 48.8  18.1 0.749
 1.2 8.8  1.2 0.816
 1.0 8.7  1.2 0.866
 5.6 55.4  6.1 0.081
 6.3 31.4  5.3 0.225
 12.8 86.7  18.6 0.605
 12.6 25.7  5.7 0.628
 10.4 70.5  5.6 0.399
 0.4 1.4  0.6 0.857
 3.8 13.1  5.1 0.090
 6.2 12.8  6.1 0.459
 10.3 44.9  11.9 0.007
) 4 (11) 0.029
all thickness; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular
t ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; E/
celeration time of E wave velocity; E/E0 , the ratio of early diastolic transmitral ﬂow
RV, regurgitant volume; SPAP systolic pulmonary arterial pressure; EIPH, exercise-
Table 3
Correlations with peak V˙O2 and V˙E=V˙CO2 slope.
Variables Correlation with
peak V˙O2
Correlation with
V˙E=V˙CO2 slope
r p-Value r p-Value
Age (years) 0.690 <0.0001 0.618 <0.0001
Log BNP (pg/mL) 0.510 <0.0001 0.512 <0.0001
Resting
HR (beat/min) 0.127 0.511 0.092 0.634
Systolic BP (mmHg) 0.166 0.390 0.277 0.145
Diastolic BP (mmHg) 0.129 0.506 0.044 0.819
LVEDVI (mL/m2) 0.273 0.076 0.145 0.354
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groups. The patients in the low exercise capacity were older, several
of them female; these patients revealed higher BNP than the patients
in the maintained exercise capacity. The patients with low exercise
capacity had greater V˙E=V˙CO2 slope than those with maintained
exercise capacity. The ratio of patients who stopped exercise
because of dyspnea was greater in the low exercise capacity group
(75%, n = 9) than in the maintained exercise capacity group (41%,
n = 15, p < 0.0001). Systolic blood pressure increased from
137  18 mmHg at rest to 178  25 mmHg at peak exercise (paired
p < 0.0001). Systolic blood pressure at peak exercise in the low exercise
capacity group (188  26 mmHg) was higher than the maintained
exercise capacity group (171  23 mmHg, p = 0.028). The heart rate
increased from 77  11 bpm at rest to 142  14 bpm at peak exercise
(paired p < 0.0001). The heart rates at peak exercise were similar
between the low exercise capacity (137  16 bpm) and the maintained
exercise capacity (144  13 bpm, p = 0.179) groups.
The exercise echocardiographic data at rest and during exercise
are shown in Table 2. The conventional echocardiographic
parameters did not differ between the two groups. Of note, no
signiﬁcant differences in the severity of MR or mitral leaﬂet
prolapse localization were found between the two groups.
Changes in SPAP at rest and exercise
Signiﬁcant changes in resting and exercise SPAP were found
both in the low exercise capacity and maintained exercise capacity
groups (Table 2). There were no signiﬁcant differences in resting
SPAP, whereas exercise SPAP was greater in the low exercise
capacity group than the maintained exercise capacity group
(Fig. 1). Of the study patients, 27% asymptomatic patients with
moderate or severe degenerative MR developed EIPH; the
prevalence of EIPH was greater in the low exercise capacity than
maintained exercise capacity groups.
Relationship between echocardiographic predictors and exercise
capacity
At rest, peak V˙O2 was correlated with the LV end-systolic
volume index, E/A, E0, and E/E0, respectively. Resting MR severity orFig. 1. Changes in systolic pulmonary arterial pressure (SPAP) at rest and during
exercise in each group. No signiﬁcant difference in resting SPAP was found between
the low and maintained exercise capacity groups. However, signiﬁcant difference in
exercise SPAP was found between the two groups. V˙O2, peak oxygen uptake.SPAP was not associated with exercise capacity (Table 3). However,
exercise SPAP was negatively correlated with peak V˙O2 (r = 0.619,
p = 0.001) and positively correlated with V˙E=V˙CO2 slope (r = 0.406,
p = 0.007; Fig. 2). In the multivariable linear regression analysis, age,
gender, E0, and EIPH were independent determinants of peak V˙O2
(p = 0.001). Furthermore, age, and EIPH were independent determi-
nants of V˙E=V˙CO2 slope (p = 0.021; Table 4).
Receiver operating characteristic curve based on rest and exercise
SPAP for reduced exercise capacity
The receiver operating characteristic analysis was performed
for predicting reduced exercise capacity on a basis of rest and
exercise SPAP. Resting SPAP was not signiﬁcant, whereas, the area
under the curve for exercise SPAP was 0.76 (95% conﬁdence
interval: 0.62–0.90) for reduced exercise capacity. Exercise SPAP
50.9 mmHg predicted reduced exercise capacity with a sensitivi-
ty of 67% and a speciﬁcity of 76%. Furthermore, the area under
curve of age- and gender-adjusted exercise SPAP was 0.88 (95%
conﬁdence interval: 0.78–0.97) for reduced exercise capacity
(Fig. 3).
Symptom-free survival
Follow-up data collection was complete in 49 patients (100%)
with a mean follow-up of 21.7  7.4 months (range, 2–25 months).
During the follow-up period, 40 patients (82%) remained asymptom-
atic and 9 patients (18%) developed symptoms (6.8  5.1 months).LVESVI (mL/m2) 0.441 0.003 0.250 0.105
LVEF (%) 0.252 0.103 0.210 0.094
E/A ratio 0.325 0.033 0.397 0.008
E0 0.443 0.003 0.464 0.002
E/E0 0.336 0.028 0.328 0.032
LAVI (mL/m2) 0.104 0.505 0.055 0.728
ERO (cm2) 0.180 0.248 0.143 0.359
RV (mL) 0.204 0.188 0.089 0.570
SPAP (mmHg) 0.031 0.842 0.016 0.919
Exercise
HR (beat/min) 0.127 0.511 0.339 0.072
Systolic BP (mmHg) 0.008 0.958 0.102 0.520
Diastolic BP (mmHg) 0.301 0.052 0.267 0.097
LVEDVI (mL/m2) 0.239 0.123 0.113 0.471
LVESVI (mL/m2) 0.307 0.045 0.256 0.097
LVEF (%) 0.139 0.375 0.225 0.147
E/A ratio 0.104 0.559 0.214 0.224
E0 0.306 0.049 0.405 0.008
E/E0 0.158 0.371 0.200 0.245
LAVI (mL/m2) 0.004 0.979 0.055 0.728
SPAP (mmHg) 0.619 <0.0001 0.406 0.007
V˙O2, oxygen uptake; V˙E, ventilatory equivalent; V˙CO2, carbon dioxide output;
BNP, brain natriuretic peptide; HR, heart rate; BP, blood pressure; LVEDVI, left
ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic
volume index; LVEF, left ventricular ejection fraction; E/A, the ratio of early
diastolic (E) and late diastolic (A) transmitral ﬂow velocities; Dct, deceleration
time of E wave velocity; E/E0 , the ratio of early diastolic transmitral ﬂow velocity
to early diastolic mitral annular velocity (E0); LAVI, left atrial volume index;
ERO, effective regurgitant oriﬁce; RV, regurgitant volume; SPAP, systolic
pulmonary arterial pressure.
Fig. 2. Relationship between exercise systolic pulmonary arterial pressure (SPAP) and exercise capacity. A correlation was found between exercise SPAP versus peak oxygen
uptake (V˙O2; r = 0.619, p = 0.001) and the minute ventilation/carbon dioxide production (V˙E=V˙CO2) slope (r = 0.406, p = 0.007), respectively.
Table 4
Multivariate linear regression; predictors of peak V˙O2 and V˙E=V˙CO2 slope.
Variables Peak V˙O2 V˙E=V˙CO2 slope
Coefﬁcient 95% CI p-Value Coefﬁcient 95% CI p-Value
Age 0.266 0.356 to 0.175 <0.0001 0.186 0.098 to 0.274 <0.0001
Gender 4.740 2.494 to 6.985 0.001 2.350 5.048 to 0.349 0.086
LVESVI 0.118 0.097 to 0.334 0.274 0.118 0.097 to 0.334 0.274
E0 0.635 1.162 to 0.108 0.020 0.043 0.594 to 0.681 0.891
RV 0.014 0.049 to 0.077 0.658 0.014 0.049 to 0.077 0.658
EIPH 3.628 5.649 to 1.608 0.001 2.778 0.440 to 5.115 0.021
V˙O2, oxygen uptake; V˙E, ventilatory equivalent; V˙CO2, carbon dioxide output; LVESVI, left ventricular end-systolic volume index; E
0 , early diastolic mitral annular
velocity; RV, regurgitant volume; EIPH, exercise-induced pulmonary hypertension.
Fig. 3. Receiver operating characteristic curve based on rest and exercise systolic
pulmonary arterial pressure (SPAP) for reduced exercise capacity. The area under
curve by exercise SPAP was 0.76 (95% conﬁdence interval: 0.62–0.90) for reduced
exercise capacity. Exercise SPAP 50.9 mmHg predicted peak oxygen uptake
80.4% with a sensitivity of 67% and a speciﬁcity of 76%. Furthermore, the area
under curve by exercise SPAP adjusted age gender was 0.88 (95% conﬁdence
interval: 0.78–0.97) for reduced exercise capacity.
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survival than those with maintained exercise capacity (p = 0.001,
Fig. 4A). Whereas, the patients with EIPH had lower 2-year symptom-
free survival than the patients without EIPH (p = 0.003, Fig. 4B).
Discussion
The results of this study demonstrated that (1) approximately
1/4 of asymptomatic patients with moderate to severe degenera-
tive MR had reduced exercise capacity; (2) exercise SPAP was more
accurate than resting SPAP for predicting exercise capacity; (3)
EIPH was an independent echocardiographic predictor of exercise
capacity; and (4) EIPH was associated with reduced symptom-free
survival.
In general, the assessment of exercise capacity in MR is based on
symptoms occurring with exertion [1]. Asymptomatic patients
with severe MR tend to incur notable mortality under conservative
management [2,3,13] because of the underestimated disease
severity. One study has demonstrated that exercise capacity
widely ranges from supernormal to markedly reduced in
asymptomatic patients with degenerative MR and approximately
1 out of 4–5 patients reveals unexpected and remarkably reduced
exercise capacity [14]. We also conﬁrmed that exercise capacity
was markedly reduced in 24% of asymptomatic patients with
degenerative MR. Accordingly, the guidelines underscore the
importance of exercise capacity and recommend patients with
degenerative MR to undergo an exercise testing for objective
assessment [1].
Although some patients with severe MR complain of no
functional limitations, others with similar MR develop severe
functional limitations [2,3,13]. The determinants of exercise
capacity reduction in MR have remained unclear with no deﬁnite
associations between peak V˙O2 and MR [15]. Generally, exercise
Fig. 4. Symptom-free survival according to exercise capacity. The patients with low exercise capacity had lower symptom-free survival than those with maintained exercise
capacity (p = 0.001) (A), whereas the patients with exercise-induced pulmonary hypertension (EIPH) had lower 2-year symptom-free survival than those without EIPH
(p = 0.003) (B).
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function is a major exercise capacity determinant [16–18] as it is
shown by its strong inﬂuence on exercise capacity in degenerative
MR [19]. The impact of diastolic dysfunction on exercise capacity is
also supported by the univariate association between peak V˙O2
and deceleration time, a marker of LV compliance [14]. In the
present study, we also demonstrated that peak V˙O2 was correlated
with diastolic function indices.
Patients with valvular heart disease are usually classiﬁed
hemodynamically as having pressure or volume overload [20–
22]. MR is classiﬁed as a volume overload state. Increases in LV
ﬁlling and left atrial pressure due to hemodynamics overload of MR
induce signiﬁcant rises in pulmonary venous, capillary, and arterial
pressures. This additional pressure load imposed on the right heart
and pulmonary circulation triggers PH which often remarkably
worsens during exercise. Hasuda et al. [23] examined the
determinant factors for exercise capacity in patients with
regurgitant valvular heart disease. They demonstrated that the
patients with a plateau in V˙O2 at peak exercise had higher
pulmonary arterial pressure than those without a plateau in
V˙O2. They concluded that exercise capacity in patients with
regurgitant valvular heart disease was limited by the magnitude of
PH during exercise. Butler et al. [24] reported that PH contributed
to exercise capacity in heart failure by impairing the cardiac output
response to exercise. The development of PH during exercise
probably limits the increment in cardiac output, resulting in the
appearance of a plateau in V˙O2. Moderate to severe MR limits
incremental increases in cardiac output during exercise. In
addition, reduced baseline forward stroke volume demonstrated
by lower peak O2 pulse independently predicts reduced exercise
capacity, probably through inability to sustain large forward stroke
volume due to MR [14].
Since V˙E=V˙CO2 slope increases with the severity of heart failure
and the level of dead space ventilation, it has been regarded as a
useful index for dyspnea during exercise [25] and a strong predictor
of mortality in patients with chronic heart failure [26]. Peak V˙O2 is
confounded by its dependence on subject effort, which is not the
case for the V˙E=V˙CO2 slope. Earlier research in patients with chronic
heart failure has demonstrated a signiﬁcant relationship between
the V˙E=V˙CO2 slope and PH [27]. The resultant increase in pulmonary
vascular resistance, as seen in PH, leads to an increase in physiologicdead space secondary to ventilation–perfusion mismatch. Falling
arterial oxygen saturations lead to earlier development of lactic
acidosis which, combined with decreased mixed venous oxygen
content and other neural signals, triggers an exaggerated ventilatory
response resulting in an elevation of the V˙E=V˙CO2 slope during
progressive exercise [28–30]. Therefore V˙E=V˙CO2 slope allows
noninvasive measurements of disease severity that are effort
independent. In the present study, we demonstrated that exercise
SPAP was positively correlated with V˙E=V˙CO2 slope and EIPH was an
independent determinant of V˙E=V˙CO2 slope. In patients with MR,
V˙E=V˙CO2 slope has not been evaluated. EIPH may contribute to
dyspnea during exercise in patients with degenerative MR, which
explains why the number of patients who terminated exercise
because of dyspnea was greater in the low exercise capacity group
than maintained exercise capacity group.
Study limitations
Our study has some acknowledged limitations, being a single-
center study with a small sample size. Although the quantiﬁcation
of MR severity during exercise is reproducible, accurate, and
clinically relevant in degenerative MR [31], we could not measure
the quantiﬁcation of MR at peak exercise because of technical
problems. The right atrial pressure was estimated from the
diameter and breath-induced variability of the inferior vena cava,
whereas the right atrial pressure was similarly estimated at rest
and during exercise. Resting right atrial pressure is extensively
variable between subjects. In addition, this estimation may also
overlook the potential inﬂuence of exercise-induced changes in
right atrial pressure. It remains difﬁcult to evaluate right atrial
pressure during exercise with the noninvasive method; thus, low
accuracy and the not-validated method require improvement.
Conclusions
In asymptomatic patients with moderate to severe degenera-
tive MR, exercise capacity varied widely and markedly decreased
in 1/4 of the study patients. EIPH was the independent
echocardiographic determinant of reduced exercise capacity.
Furthermore, EIPH was associated with reduced symptom-free
survival.
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